A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SY-5007 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, single-arm, first-in-human study designed to evaluate the
safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of SY-5007
administered orally to participants with advanced solid tumors, including RET-fusion positive
NSCLC or RET-mutant medullary thyroid cancer (MTC) or other RET- altered advanced solid
tumor.